---
schema_version: '1.0'
id: news-20260829-7d1a80
title: Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term
  Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic
  Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
url: https://www.finanznachrichten.de/nachrichten-2026-08/69443294-bristol-myers-squibb-presents-data-up-to-five-years-reinforcing-the-long-term-efficacy-and-safety-of-camzyos-mavacamten-in-symptomatic-obstructive-h-004.htm
url_hash: 7d1a8074fc52d731b8dae4ae8856f438ff253d65783d3296d239edda4f17b125
canonical_url: https://www.finanznachrichten.de/nachrichten-2026-08/69443294-bristol-myers-squibb-presents-data-up-to-five-years-reinforcing-the-long-term-efficacy-and-safety-of-camzyos-mavacamten-in-symptomatic-obstructive-h-004.htm
source: www.finanznachrichten.de
category: news/tech
category_raw: it_general
region: null
tags:
- it
- it_general
- it_tech
lang: null
published_at: null
fetched_at: '2026-08-29T19:16:13.098457Z'
updated_at: '2026-08-29T19:21:04Z'
status: published
content_hash: null
content_changed_at: null
license_note: link-only
summary: null
summary_source: null
summary_en: null
summary_omitted_reason: license_restricted
redistribution: false
keywords_en:
- and
- artificial intelligence
- Bristol
- Bristol Myers Squibb
- Camzyos
- Cardiology
- Cardiomyopathy
- Congress
- DATA
- Efficacy
- ESC
- European
- Five
- FIVESTAR WEDDING
- Hypertrophic
- it
- it_general
- it_tech
- Long-Term
- mavacamten
- Myers
- Obstructive
- oHCM
- Presents
entities_en:
- name: Bristol Myers Squibb
  type: organization
- name: DATA
  type: concept
- name: FIVESTAR WEDDING
  type: organization
topics_en:
- artificial intelligence
- technology
numeric_facts: []
entities:
- name: Bristol Myers Squibb
  type: organization
- name: DATA
  type: concept
- name: FIVESTAR WEDDING
  type: organization
key_facts: []
related: []
related_auto:
- name: Camzyos
  type: UNKNOWN
  weight: 1.0
- name: HCM_CITY
  type: location
  weight: 1.0
- name: 愛グループ
  type: organization
  weight: 1.0
- name: フォトスタジオ愛
  type: organization
  weight: 1.0
computed_at: '2026-08-29T19:21:03Z'
---

# Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

## TL;DR
（要約なし・原文はリンク先を参照 / No summary available; see the source link.）

## Key Points
- it / it_general / it_tech

## Details
(本文なし。リンク先参照)

## Source
元記事: [Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026](https://www.finanznachrichten.de/nachrichten-2026-08/69443294-bristol-myers-squibb-presents-data-up-to-five-years-reinforcing-the-long-term-efficacy-and-safety-of-camzyos-mavacamten-in-symptomatic-obstructive-h-004.htm)